• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[内科住院患者静脉血栓栓塞危险因素的合理化分析。一项前瞻性研究]

[Rationalization of risk factors for venous thromboembolism in medical inpatients. A prospective study].

作者信息

Pottier P, Planchon B, Truchaud F, Pistorius M A, Furic I, Grolleau J Y

机构信息

Service de Médecine Interne, CHU de Nantes, Hôtel-Dieu, 44093 Nantes Cedex 1.

出版信息

J Mal Vasc. 2000 Oct;25(4):241-9.

PMID:11060418
Abstract

BACKGROUND

In terms of preventive management of venous thromboembolism in medical inpatients, very large differences may be observed. Rationalization of behaviour requires the evaluation of simple and logical parameters, which takes into account both patient safety and economic considerations.

AIM

The aim of this study was to evaluate a preventive scheme including the rationalization of the indications and the use of low molecular weight heparin.

EXPERIMENTAL DESIGN

Epidemiologic investigation.

SETTING AND PATIENTS

Patients hospitalized in five medical departments in the Hospital Center of Nantes, France.

INTERVENTION

The risk of venous thromboembolism was rated as high, intermediate and low. Patients with high or intermediate risk were eligible for prevention therapy (table I).

MEASURES

The main criterion was the occurrence during hospital stay of deep or superficial venous thrombosis of the lower limbs, pulmonary embolism, or unexplained sudden death. The screening was based on clinical features double-checked by venous doppler ultrasonography of the lower limbs and/or ventilation-perfusion lung scanning.

RESULTS

24,497 patients were eligible (table II), 15% were considered at risk and treated with Nadroparin, 6% had the same risk profile but were not treated and 14. 7% had low risk and no prevention. No bleeding event was reported. The incidence of venous thromboembolism was 0.75%, 1.7% and 0.14% respectively (p <0.01) (table III). This efficacy does not appear to depend on body weight or the existence of multiple risk factors observed (table IV and V).

CONCLUSIONS

This analysis of risk factors separates two populations with rates of incidence dramatically and significantly different. The prevention of venous thromboembolism by fixed dose of low molecular weight heparin remains justified since it reduces the risk of venous thromboembolism by a factor of 2.5.

摘要

背景

在医疗住院患者静脉血栓栓塞的预防管理方面,可能会观察到非常大的差异。行为合理化需要评估简单且合理的参数,这要同时考虑患者安全和经济因素。

目的

本研究的目的是评估一种预防方案,该方案包括适应证的合理化以及低分子量肝素的使用。

实验设计

流行病学调查。

研究地点和患者

法国南特医院中心五个内科病房的住院患者。

干预措施

将静脉血栓栓塞风险分为高、中、低三级。高风险或中风险患者 eligible for 预防治疗(表I)。

测量指标

主要标准是住院期间下肢深静脉或浅静脉血栓形成、肺栓塞或不明原因猝死的发生情况。筛查基于临床特征,并通过下肢静脉多普勒超声和/或通气-灌注肺扫描进行双重检查。

结果

24497名患者符合条件(表II),15%被认为有风险并接受那屈肝素治疗,6%有相同风险特征但未接受治疗,14.7%风险低且未进行预防。未报告出血事件。静脉血栓栓塞的发生率分别为0.75%、1.7%和0.14%(p<0.01)(表III)。这种疗效似乎不取决于体重或观察到的多种风险因素的存在(表IV和V)。

结论

这种风险因素分析将两个发病率差异巨大且显著的人群区分开来。固定剂量低分子量肝素预防静脉血栓栓塞仍然合理,因为它将静脉血栓栓塞风险降低了2.5倍。

注

“eligible for”直译为“有资格获得”,这里结合语境意译为“适合进行” 。

相似文献

1
[Rationalization of risk factors for venous thromboembolism in medical inpatients. A prospective study].[内科住院患者静脉血栓栓塞危险因素的合理化分析。一项前瞻性研究]
J Mal Vasc. 2000 Oct;25(4):241-9.
2
[Assessing the use of low-molecular-weight heparins fo venous thromboembolism prophylaxis in internal medicine patients].[评估低分子量肝素在内科患者中预防静脉血栓栓塞的应用]
Farm Hosp. 2004 Nov-Dec;28(6):402-9.
3
Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).全髋关节或膝关节置换术后主要静脉血栓栓塞的预防:低分子量肝素与普通肝素的随机对照比较(ECHOS试验)
Int Angiol. 2006 Dec;25(4):335-42.
4
A prospective observational study of a cohort of outpatients with an acute medical event and reduced mobility: incidence of symptomatic thromboembolism and description of thromboprophylaxis practices.一项针对患有急性医疗事件且活动能力下降的门诊患者队列的前瞻性观察研究:症状性血栓栓塞的发生率及血栓预防措施描述。
J Intern Med. 2006 Aug;260(2):168-76. doi: 10.1111/j.1365-2796.2006.01678.x.
5
Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial.固定低剂量达肝素预防肥胖或老年住院患者静脉血栓栓塞的疗效和安全性:PREVENT试验的亚组分析
Arch Intern Med. 2005 Feb 14;165(3):341-5. doi: 10.1001/archinte.165.3.341.
6
Venous thromboembolism associated with long-term use of central venous catheters in cancer patients.癌症患者长期使用中心静脉导管相关的静脉血栓栓塞
J Clin Oncol. 2003 Oct 1;21(19):3665-75. doi: 10.1200/JCO.2003.08.008.
7
[Prevention of venous thromboembolism in internal medicine and neurology].[内科及神经内科中静脉血栓栓塞症的预防]
Vnitr Lek. 2006 Mar;52 Suppl 1:63-7.
8
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.达肝素预防急性内科疾病患者静脉血栓栓塞的随机、安慰剂对照试验。
Circulation. 2004 Aug 17;110(7):874-9. doi: 10.1161/01.CIR.0000138928.83266.24. Epub 2004 Aug 2.
9
[Prevalence and prevention of venous thromboembolic events in general practice. Multicenter, prospective cohort study].[基层医疗中静脉血栓栓塞事件的患病率及预防。多中心前瞻性队列研究]
Rev Prat. 2008 Dec 15;58(19 Suppl):3-8.
10
Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism.接受静脉血栓栓塞预防治疗的内科患者中肝素诱导的血小板减少症的发病率及经济影响
Pharmacotherapy. 2006 Oct;26(10):1438-45. doi: 10.1592/phco.26.10.1438.